her2-targeting adcs for urothelial carcinoma
Published 1 year ago • 30 plays • Length 0:24Download video MP4
Download video MP3
Similar videos
-
0:55
adcs for advanced urothelial carcinoma
-
15:34
is her2 targeting on the horizon in urothelial carcinoma?
-
2:21
adcs for the treatment of her2-low breast cancer
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
6:51
adcs for her2 and her2-low breast cancer
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
1:58
what’s next for antibody drug conjugates in urothelial carcinoma?
-
1:33
antibody-drug conjugates (adcs) in nsclc
-
5:00
bladder cancer: her2-targeted adcs for genitourinary cancers
-
2:10
targeting low her2 expression with antibody-drug conjugates
-
5:00
ovarian cancer: advances in her2-targeted adcs
-
2:41
correlations between her2 alterations and pd-l1 expression in bladder cancer
-
4:00
urothelial carcinoma trial data presented at asco gu 2022
-
1:23
antibody-drug conjugates for the treatment of breast cancer
-
2:43
study of ds-8201a in her2-low, unresectable and/or metastatic breast cancer
-
2:04
areas of unmet need in metastatic urothelial carcinoma
-
1:41
targeting her2 by combination therapies
-
3:03
phase ii trial of patritumab deruxtecan in metastatic breast cancer